Climb Bio (CLYM) Total Non-Current Liabilities (2020 - 2024)

Climb Bio has reported Total Non-Current Liabilities for 5 years, with the latest figure at $5.3 million in Q4 2024.

• For the quarter ending Q4 2024, Total Non-Current Liabilities rose 86.31% year-over-year to $5.3 million; the trailing twelve-month figure through Dec 2024 stood at $5.3 million (up 86.31% YoY), and the FY2024 full-year result was $5.3 million, up 86.31% from the prior year.
• Total Non-Current Liabilities for Q4 2024 stood at $5.3 million, up from $3.4 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $7.9 million in Q2 2022, with the low at $2.8 million in Q4 2023.
• Historically, Total Non-Current Liabilities has averaged $4.8 million across 5 years, with a median of $4.4 million in 2023.
• Annual changes were most pronounced in 2021 — Total Non-Current Liabilities jumped 96.9% — and 2023, when it plunged 54.63%.
• Climb Bio's Total Non-Current Liabilities stood at $3.1 million in 2020, then jumped by 96.9% to $6.0 million in 2021, then climbed by 4.08% to $6.3 million in 2022, then sank by 54.63% to $2.8 million in 2023, then surged by 86.31% to $5.3 million in 2024.
• The last three Total Non-Current Liabilities figures came in at $5.3 million (Q4 2024), $3.4 million (Q3 2024), and $3.7 million (Q2 2024), per Business Quant data.